We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
-25.07%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$28M
Cap. Flow
+$13.3M
Cap. Flow %
10.47%
Top 10 Hldgs %
74.71%
Holding
39
New
7
Increased
11
Reduced
6
Closed
15
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.5 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 97.28%
2 Miscellaneous 2.72%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
LKFT icon
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.25B
$20.6M 16.22%
369,000
-5,000
-1% -$296K
2021 Q1
5 quarters
PRTA icon
2
Prothena
PRTA
$429M
$14.9M 11.77%
550,000
-16,538
-3% -$484K
2020 Q3
7 quarters
KZR icon
3
DELISTED
Kezar Life Sciences
KZR
$10.4M 8.23%
126,269
+96,269
+321% +$8.49M
2021 Q1
5 quarters
ALBO
4
DELISTED
Albireo Pharma Inc
ALBO
$9.29M 7.32%
467,795
-12,205
-3% -$322K
2018 Q3
15 quarters
KALV icon
5
DELISTED
KalVista Pharmaceuticals
KALV
$8.08M 6.36%
820,752
+231,482
+39% +$2.55M
2021 Q2
4 quarters
ALDX icon
6
Aldeyra Therapeutics
ALDX
$40.5M
$7.92M 6.24%
1,985,883
+585,644
+42% +$2.01M
2018 Q4
14 quarters
MGTX icon
7
MeiraGTx Holdings
MGTX
$813M
$7.47M 5.88%
986,218
+605,518
+159% +$5.87M
2022 Q1
1 quarter
CRL icon
8
Charles River Laboratories
CRL
$16B
$5.88M 4.64%
27,500
-4,000
-13% -$977K
2021 Q4
2 quarters
ONEM
9
DELISTED
1Life Healthcare
ONEM
$5.68M 4.48%
+725,000
New +$6.23M
2022 Q2
0 quarters
QDEL icon
10
QuidelOrtho
QDEL
$657M
$4.53M 3.57%
46,576
+20,901
+81% +$2.13M
2022 Q1
1 quarter
STTK icon
11
Shattuck Labs
STTK
$455M
$4.14M 3.26%
1,020,000
+221,282
+28% +$801K
2021 Q3
3 quarters
CUE icon
12
Cue Biopharma
CUE
$34.6M
$4.12M 3.25%
55,183
+4,840
+10% +$566K
2019 Q4
10 quarters
RCKT icon
13
Rocket Pharmaceuticals
RCKT
$236M
$3.81M 3%
276,802
+73,534
+36% +$877K
2021 Q4
2 quarters
ONEM
14
CALL
DELISTED
1Life Healthcare
ONEM
$3.45M 2.72%
+440,000
New +$3.78M
2022 Q2
0 quarters
GBT
15
DELISTED
Global Blood Therapeutics
GBT
$3.25M 2.56%
+101,847
New +$2.98M
2022 Q2
0 quarters
MIRM icon
16
Mirum Pharmaceuticals
MIRM
$6.04B
$3.14M 2.48%
161,527
+87,597
+118% +$2.07M
2022 Q1
1 quarter
THC icon
17
Tenet Healthcare
THC
$21.6B
$2.66M 2.1%
+50,700
New +$3.53M
2022 Q2
0 quarters
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$1.88B
$1.87M 1.47%
+176,680
New +$1.82M
2022 Q2
0 quarters
SPRY icon
19
ARS Pharmaceuticals
SPRY
$371M
$1.45M 1.14%
341,108
+15,743
+5% +$54.9K
2021 Q4
2 quarters
PRQR icon
20
ProQR Therapeutics
PRQR
$155M
$1.33M 1.05%
1,707,509
+1,108,221
+185% +$826K
2020 Q4
6 quarters
ARDX icon
21
Ardelyx
ARDX
$784M
$1.28M 1.01%
+2,163,520
New +$1.59M
2022 Q2
0 quarters
INMD icon
22
InMode
INMD
$741M
$1.01M 0.79%
45,000
-5,000
-10% -$131K
2022 Q1
1 quarter
APEN
23
DELISTED
Apollo Endosurgery
APEN
$329K 0.26%
+90,176
New +$426K
2022 Q2
0 quarters
CGTX icon
24
Cognition Therapeutics
CGTX
$57.1M
$254K 0.2%
120,198
-119,882
-50% -$310K
2021 Q4
2 quarters
AGL icon
25
Agilon Health
AGL
$1.52B
– –
-5,600
Closed -$3.55M –

Similar funds

Prosight Management's Q2 2022 Portfolio in Review

As of Q2 2022, Prosight Management held 39 positions worth $127M, down 18% from $155M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Prosight Management deployed $13.3M of net new capital in Q2 2022, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was 1Life Healthcare: 725,000 shares worth $5.68M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Charles River Laboratories, an estimated $977K trimmed.

  • Prosight Management's largest Q2 2022 buy was 1Life Healthcare: 725,000 shares worth $5.68M.
  • Prosight Management added most to Kezar Life Sciences in Q2 2022, an estimated $8.49M increase.
  • Prosight Management's biggest Q2 2022 reduction was Charles River Laboratories, cutting an estimated $977K.
  • Prosight Management fully exited Convey Health Solutions Holdings in Q2 2022, selling an estimated $4.89M.
  • Prosight Management's ten largest holdings make up 75% of its $127M portfolio in Q2 2022.
  • Prosight Management opened 7 new positions and closed 15 in Q2 2022.
  • Prosight Management's portfolio value fell 18% quarter-over-quarter to $127M.

Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.